AAA Announces Pivotal Phase 3 NETTER-1 Study of Lutathera in Patients with Midgut Neuro Endocrine Tumors Meets Primary Endpoint and Data will be Presented in Presidential Session at the European Cancer Congress 2015 — FDA Grants Priority Review to AAA’s New Drug Application for Somakit-TATE, Lutathera’s companion PET Diagnostic.

ITA